Skip to main content
Caplight Logo









TME Therapeutics Inc.

TME Therapeutics Inc.

Private
TokyoHealthcare & Life Scienceshttps://tme-tx.com/

Last Round

Grant

Jul 1, 2025

Total Funding Raised

$223,000

Company Overview

TME Therapeutics Inc. is a biotechnology company that develops novel therapeutics for the treatment of cancer and fibrosis by regulating the tumor microenvironment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

tumor microenvironmentTMERNA oligonucleotidesiRNA therapeuticpancreatic cancerCHST15stroma-modifying agentbiotech drug discoveryclinical-stage biotechcancer immunotherapyfibrosis treatmentdrug development pipelinebiopharma licensingRNA medicinesolid tumor therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TME Therapeutics Inc. Comparables

Compare TME Therapeutics Inc. with similar companies based on industry and business-model similarity.

TME Therapeutics Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Silexion Therapeutics Corp.
71%
InxMed Limited
71%
Phio Pharmaceuticals Corp.
64%

TME Therapeutics Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 1, 2025
GrantNov 17, 2022

TME Therapeutics Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 1, 2025

    $223K grant from Japan Society for the Promotion of Science.

  • Nov 17, 2022

    Received grant funding from Japan Agency for Medical Research and Development.

TME Therapeutics Inc. Filings

Explore SEC and related filing metadata, where available.

TME Therapeutics Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about TME Therapeutics Inc.'s valuation, stock price, and market status.

Is TME Therapeutics Inc. a public or private company?

TME Therapeutics Inc. is a private company.

What is the current stock price of TME Therapeutics Inc.?

TME Therapeutics Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is TME Therapeutics Inc. worth (valuation)?

Valuation information for TME Therapeutics Inc. is not publicly available.

Can I buy TME Therapeutics Inc. stock?

TME Therapeutics Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was TME Therapeutics Inc.'s last funding round?

Funding round information for TME Therapeutics Inc. is not publicly available.

Who are the main investors in TME Therapeutics Inc.?

Investor information for TME Therapeutics Inc. is not publicly disclosed.

Will TME Therapeutics Inc. IPO soon?

No public IPO plans have been announced for TME Therapeutics Inc..

How can I track TME Therapeutics Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TME Therapeutics Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTokyo
Year Founded2018
Last FundingJul 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?